Περίληψη:
Background: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. Aims: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. Methods: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary-ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing. Results: A total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and NAFLD scores (Bonferroni test P < 0.05). Conclusions: In patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity and fibrosis. © 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
Συγγραφείς:
Munteanu, M.
Tiniakos, D.
Anstee, Q.
Charlotte, F.
Marchesini, G.
Bugianesi, E.
Trauner, M.
Romero Gomez, M.
Oliveira, C.
Day, C.
Dufour, J.-F.
Bellentani, S.
Ngo, Y.
Traussnig, S.
Perazzo, H.
Deckmyn, O.
Bedossa, P.
Ratziu, V.
Poynard, T.
Castille, J.-M.
Langon, T.
Lawlor, D.
Marra, F.
Sørensen, T.
Tribelli, C.
De Minicis, S.
Burt, A.D.
Gouw, A.S.H.
Lackner, C.
Schirmacher, P.
Terracciano, L.
Brain, J.
Bury, Y.
Cabibi, D.
David, E.
Losi, L.
Montani, M.
Pareja, M.J.
Wendum, D.
Wrba, F.
Ziol, M.
Thabut, D.
Moussalli, J.
Lebray, P.
Rudler, M.
Bismuth, F.I.
Rosmorduc, O.
Calmus, Y.
Hartemann, A.
Jacqueminet, S.
Bruckert, E.
Giral, P.
Naveau, S.
Perlemuter, G.
Varsat, B.
Mercadier, A.
the FLIP Consortium
the FibroFrance Group
